Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New scanner aims to cut repeat breast cancer surgeries

NCT ID NCT07352930

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This trial tests a new device called the EndoSCell Scanner, which uses fluorescence imaging to help surgeons see if any cancer cells remain after removing a breast tumor. About 172 women with breast cancer will have their surgical cavity scanned during surgery. If the scanner detects possible leftover cancer, the surgeon can remove more tissue right away. The goal is to lower the chance of needing a second surgery to clear remaining cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EndoSCell Scanner (ES Scanner) device
What this could lead to
If successful, this device could help surgeons remove all cancer cells during breast-conserving surgery, reducing the need for a second operation.
What could go wrong
This is an early-stage trial with only 172 participants, so results may not apply to all patients. The device's accuracy in detecting cancer cells is still being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 172 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Pathologically confirmed diagnosis of primary invasive breast cancer, ductal carcinoma in situ (DCIS), or invasive breast cancer with a DCIS component. Acceptable diagnostic methods include core needle biopsy or fine-needle aspiration biopsy. 2. Female, age ≥ 18 years. 3. Scheduled to undergo breast-conserving surgery for the malignant breast lesion. 4. Willing and able to comply with the study procedures and follow-up. 5. Has provided written informed consent. 6. No other uncontrolled serious medical conditions aside from the cancer diagnosis (see Exclusion Criteria for details). 7. Adequate organ and bone marrow function, defined as: * White blood cell count \> 3,000/μL * Platelet count \> 75,000/μL * Total bilirubin ≤ institutional upper limit of normal (ULN) * AST (SGOT) / ALT (SGPT) \< 2.5 × institutional ULN * Serum creatinine ≤ 1.5 mg/dL, OR creatinine clearance \> 60 mL/min/1.73 m² (for participants with serum creatinine levels above institutional ULN) 8. ECOG performance status of 0 or 1. Exclusion Criteria: 1. Pregnancy or lactation. 2. Suspected pregnancy. 3. Prior injection of ICG or other fluorescent dyes for sentinel lymph node mapping on the day of surgery, before the planned lumpectomy cavity scan with the study device. 4. Unresolved adverse events from previous medications or diagnostic agents. 5. Uncontrolled hypertension, defined as persistent systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 110 mmHg. Patients with known hypertension must be stable on medication within these limits. 6. History of allergy to any oral or intravenous contrast agent. 7. Uncontrolled comorbidities, including but not limited to: * Active infection * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia * Hospitalization for COPD or asthma within the past 12 months * Psychiatric illness/social situations that would limit compliance with study requirements. 8. Any condition where, in the investigator's judgment, participation would not be in the best interest of the participant. 9. Planned re-excision lumpectomy due to positive margins from a prior surgery performed before enrollment. 10. Prior surgical history in the ipsilateral breast, including breast cancer surgery, mastectomy, breast reconstruction, or implant placement.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast conserving surgery are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Guangdong Provincial People's Hospital

    RECRUITING

    Guangzhou, Guangdong, 510080, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.